HD-OPM Archive
Topics › Statins

Ezetimibe-type absorption inhibitors linked to 31% lower liver cancer odds; statins 35%

Louis Nervegna · Aug 01, 2024 · ♥ 11 reactions · 3 comments · original Facebook post
StatinsPCSK9, ezetimibe & newer drugsCancer
AI summary & key facts

A genetic/drug-target analysis reported by Medical Xpress found cholesterol absorption inhibitors associated with 31% lower odds of liver cancer and statins with 35% lower odds. Fibrates, omega-3 and niacin showed no association, while bile acid sequestrants showed inconsistent results needing replication.

Cholesterol absorption inhibitors (e.g. ezetimibe) and statins are associated with lower risk of liver cancer.

Quoted:

“Use of cholesterol absorption inhibitors was associated with 31% lower odds of liver cancer risk in the overall analysis. These medications were also linked with a lower risk of liver cancer in analyses based on diabetes and liver disease status. The study also confirmed that statins were associated with 35% lower odds of liver cancer.

No associations with liver cancer risk were observed for fibrates, omega-3 fatty acids, or niacin. While bile acid sequestrant use was associated with higher odds of liver cancer risk in the overall analysis, the results of analyses based on diabetes and liver disease status were inconsistent, suggesting that replication of these observations is important.”

medicalxpress.comStatin cholesterol lowering drug linkedmedicalxpress.com

#statinsHD #ezetimibeHD #cancerHD #livercancerHD #statinscancerHD #liverHD #statinsliverHD

Research cited

← newer: Simple metabolic health markers: waist-to-height ratio, adipolder: Inflammation is a causal CVD risk factor; CRP predicts risk →